drugset / Trial / NCT04230122

A Study of LY3478006 in Healthy Participants

NCT04230122 ↗

Phase 1 Terminated 4 enrolled Eli Lilly and Company
RandomizedParallel-groupDouble-blindBasic science

Summary

The purpose of this study is to learn more about how safe and how well tolerated LY3478006 is when given by injection into a vein or just under the skin to healthy participants. Blood tests will be done to check how much LY3478006 is in the bloodstream and how long the body takes to get rid of it. For each participant, the study will last up to about 16 weeks, including screening.

Timeline

Start
2020-02-17
Primary completion
2020-06-04
Completion
2020-06-04

Outcome

Outcome not reported

Stopped: “Protocol stopping criteria (safety) were met.”

Drugs

EvaluationDrugModalityDoseRoute
Subject LY3478006 Unknown 10 mg Intravenous

Indications

No indication recorded.